The First REMS Template
This article was originally published in RPM Report
Executive Summary
Each of the first four products approved with a mandatory Risk Evaluation & Mitigation Strategies received almost identical instructions from FDA in letters approving the application. Here is the section from the first letter issued, to Pozen Inc. for the migraine combination therapy Treximet (marketed by GlaxoSmithKline PLC).